

Drug development Against Amebiasis

Dexter Petri*

Department of Pharmacology, Colorado State University, USA

Abstract

Amebiasis, caused by the protozoan parasite *Entamoeba histolytica*, remains a significant global health challenge, particularly in developing countries with poor sanitation infrastructure. Current treatment options primarily rely on Nitroimidazole drugs such as Metronidazole and Tinidazole, albeit concerns regarding drug resistance and adverse effects persist. Consequently, there is an urgent need for novel therapeutic interventions against this devastating disease. This abstract reviews recent advancements in drug development targeting *E. histolytica*. Nitazoxanide, with its ability to disrupt the pyruvate-ferredoxin oxidoreductase enzyme in the parasite, has emerged as a promising alternative. Additionally, aminoglycoside antibiotics like Paromomycin, which inhibit protein synthesis in the parasite, have demonstrated efficacy in combination therapy.

Keywords: Protozoan parasite; Nitroimidazole drugs; Metronidazole; Tinidazole, albeit; Oxidoreductase enzyme

Introduction

Amebiasis, caused by the protozoan parasite *Entamoeba histolytica*, is a significant global health concern, particularly prevalent in regions with poor sanitation and hygiene practices. This disease manifests primarily as intestinal infection but can lead to severe invasive disease, including liver abscesses and systemic infections, with potentially fatal consequences if left untreated. Current treatment options, mainly reliant on Nitroimidazole drugs such as Metronidazole, face challenges including drug resistance and adverse effects, necessitating the exploration of novel therapeutic avenues. In recent years, there has been increasing interest and research focus on drug development against amebiasis, aiming to discover more efficacious, safer, and targeted treatments. This introduction provides an overview of the current landscape of drug development efforts against *E. histolytica*, highlighting key challenges and opportunities in this field. The urgency of addressing amebiasis is underscored by its significant impact on global health, particularly in low-resource settings where access to clean water, sanitation, and healthcare services is limited. Furthermore, the emergence of drug-resistant strains of *E. histolytica* adds complexity to treatment strategies and emphasizes the need for innovative approaches. In this context, this introduction will explore recent advancements in drug development against amebiasis, including the identification of novel drug targets, repurposing existing drugs, and the exploration of alternative treatment modalities such as vaccines. Additionally, it will discuss the importance of interdisciplinary collaboration between researchers, healthcare providers, policymakers, and funding agencies to accelerate progress in this field and ultimately mitigate the burden of amebiasis on a global scale [1, 2].

Description

Amebiasis is a disease caused by the protozoan parasite *Entamoeba histolytica*, which primarily affects the intestines but can also spread to other organs, causing severe illness and even death if left untreated. Given the significant health burden posed by amebiasis, the development of effective drugs against this parasite is crucial. Here are some approaches and drug developments in the fight against amebiasis:

Nitroimidazole drugs

Metronidazole is the most commonly used drug for amebiasis. It works by disrupting the DNA of the parasite, leading to its death.

Although effective, resistance to metronidazole has been reported in some cases [3].

Tinidazole

This is another Nitroimidazole drug similar to metronidazole and is used as an alternative treatment for amebiasis. It's often effective against strains that are resistant to metronidazole [4, 5].

Nitazoxanide

This broad-spectrum antiparasitic agent has shown effectiveness against various parasites, including *E. histolytica*. Nitazoxanide interferes with the Pyruvate-Ferredoxin Oxidoreductase (PFOR) enzyme in the parasite, leading to its death [6].

Paromomycin

This aminoglycoside antibiotic is often used in combination therapy with other drugs for amebiasis treatment. It inhibits protein synthesis in the parasite, ultimately killing it [7].

Newer drug developments

There's ongoing research into developing new drugs for amebiasis, particularly those that target specific pathways or enzymes unique to the parasite while minimizing side effects on the host. For example, compounds that target the parasite's cysteine proteases, essential for its survival, are being investigated [8].

Drug repurposing

Researchers are exploring the potential of repurposing existing drugs approved for other diseases to treat amebiasis. This approach can expedite the drug development process since safety profiles and

*Corresponding author: Dexter Petri, Department of Pharmacology, Colorado State University, USA, Email: dexterpetri@csu.ac.org

Received: 04-Mar-2024, Manuscript No: wjpt-24-128181, **Editor assigned:** 05-Mar-2024, PreQC No: wjpt-24-128181(PQ), **Reviewed:** 25-Mar-2024, QC No: wjpt-24-128181, **Revised:** 26-Mar-2024, Manuscript No: wjpt-24-128181(R), **Published:** 31-Mar-2024, DOI: 10.4172/wjpt.1000237

Citation: Petri D (2024) Drug development Against Amebiasis. World J Pharmacol Toxicol 7: 237.

Copyright: © 2024 Petri D. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

pharmacokinetics of these drugs are already known. Drugs such as antimalarials and antifungals have shown promise in preclinical studies against *E. histolytica* [9].

Vaccine development

Although not strictly a drug, vaccine development against *E. histolytica* is also an active area of research. Vaccines could potentially prevent infection and reduce the spread of amebiasis, particularly in regions where the disease is endemic.

Overall, the fight against amebiasis involves a multifaceted approach, including drug development, improved diagnostics, sanitation, and public health measures to prevent transmission. Collaboration between researchers, healthcare providers, and policymakers is essential in combating this disease effectively [10].

Conclusion

In conclusion, drug development against amebiasis represents a critical area of research aimed at addressing the significant global burden of this parasitic disease. While current treatment options have provided some relief, challenges such as drug resistance and adverse effects underscore the need for innovative therapeutic interventions. Recent advancements in drug development have shown promising results, including the identification of new drug candidates targeting specific parasite enzymes and the repurposing of existing drugs with known safety profiles. Additionally, the development of vaccines against *E. histolytica* offers a preventive measure to complement drug-based treatments, potentially reducing the incidence of infection in endemic regions. However, several challenges remain, including the need for improved understanding of parasite biology, mechanisms of drug resistance, and optimization of drug delivery systems to enhance efficacy and reduce side effects. Moreover, ensuring equitable access to new treatments and interventions in resource-limited settings is essential for effective disease control and elimination efforts.

References

1. Aguilar A, Borrell A, Reijnders PJH (2002) Geographical and temporal variation in levels of organochlorine contaminants in marine mammals. *Mar Environ Res.* 53: 425-452.
2. Boon JP, Sleiderink HM, Helle MS, Dekker M, van Schanke A, et al. (1998) The use of a microsomal in vitro assay to study phase I biotransformation of chlorobornanes (Toxaphene®) in marine mammals and birds: possible consequences of biotransformation for bioaccumulation and genotoxicity. *Comp Biochem Physiol C.* 121: 385-403.
3. Brown TM, Ross PS, Reimer KJ, Veldhoen N, Dangerfield NJ, et al. (2014) PCB related effects thresholds as derived through gene transcript profiles in locally contaminated ringed seals (*Pusa hispida*). *Environ Sci Technol.* 48: 12952-12961.
4. Cadieux M, Muir D, Beland P, Hickie BE (2015) Lactational transfer of polychlorinated-biphenyls (PCBs) and other organochlorines in St. Lawrence beluga whales (*Delphinapterus leucas*). *Arch Environ Contam Toxicol.*
5. Das K, Siebert U, Gillet A, Dupont A, Di-Poi C, et al. (2008) Mercury immune toxicity in harbour seals: links to in vitro toxicity. *Environ Health.* 7: 52.
6. De Swart RL, Ross PS, Vos JG, Osterhaus ADME (1996) Impaired immunity in harbour seals (*Phoca vitulina*) exposed to bioaccumulated environmental contaminants: review of a long-term feeding study. *Environ Health Perspect.* 104: 823-828.
7. Dupont A, Siebert U, Covaci A, Weijs L, Eppe G, (2013) Relationships between in vitro lymphoproliferative responses and levels of contaminants in blood of free-ranging adult harbour seals (*Phoca vitulina*) from the North Sea. *Aquat Toxicol.* 142: 210-220.
8. Fossi MC, Marsili L, Casini S, Bucalossi D (2006) Development of new tools to investigate toxicological hazard due to endocrine disruptor organochlorines and emerging contaminants in Mediterranean cetaceans. *Mar Environ Res.* 62: 200-204.
9. Freeman HC, Sangalang GB (1977) A study of the effects of methyl mercury, cadmium, arsenic, selenium, and a PCB (aroclor 1254) on adrenal and testicular steroidogenesis in vitro, by the gray seal *Halichoerus grypus*. *Arch Environ Contam Toxicol.* 5: 369-383.
10. Gauthier JM, Dubeau H, Rassart E (1999) Induction of micronuclei in vitro by organochlorine compounds in beluga whale skin fibroblasts. *Mutat Res.* 439: 87-95.